We are Sorry, This Page doesn't Exist
One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment
Peanut allergy is a serious and dangerous, but one biotech may hold the answer that could lead to to a 100% or 200% gain as its peanut allergy drug is expected to become more than just a blockbuster........»»
First peanut allergy treatment approved by FDA
The CEO of Aimmune Therapeutics told FOX Business that the company hopes to achieve the ability for children to be protected from accidental exposure to peanuts......»»
FDA Approves First-Ever Peanut Allergy Treatment
Aimmune Therapeutics shares jumped early on Monday after the FDA announced late Friday a critical approval for the firm’s peanut allergy treatment......»»
FDA approves first treatment for peanut allergy
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Aimmune still has most efficacious peanut allergy treatment, says Cantor
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Why This Peanut Allergy Study Was Worth the Wait
DBV Tech shares jumped on Thursday after the firm announced positive topline results from its late-stage study in children with a peanut allergy......»»
Major Step Forward in Peanut Allergy Treatment
DBV Technologies shares dipped on Monday after the firm announced an update from the FDA. Although it was a positive update for the company, this appears to be a case of “sell the news.â€.....»»
Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential Approval
Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential Approval.....»»
FDA panel recommending approval of first peanut allergy treatment for kids
An estimated 1.6 million children and teenagers would be eligible for the medication, to be sold as Palforzi.....»»
Aimmune"s stock halted as FDA panel"s decision awaited on peanut allergy treatment
Aimmune Therapeutics Inc.'s stock has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is meeting a.....»»
Aimmune jumps as FDA materials seen as good sign for peanut allergy treatment
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
FDA to ask panel if Aimmune peanut allergy treatment data support approval
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Revolutionary Peanut Allergy Treatment Is One Step Closer
DBV Tech shares shot up on Thursday after the company announced the submission of paperwork to the FDA for Viaskin Peanut for the treatment of peanut-allergic children......»»
Aimmune Therapeutics Could Achieve Regulatory Firsts With Peanut Allergy Treatment
Aimmune Therapeutics Could Achieve Regulatory Firsts With Peanut Allergy Treatment.....»»
Peninsula biotech lines up chance to crack the peanut allergy nut
After asking U.S. regulators to approve its peanut-desensitizing treatment and completing a late-stage trial in Europe, Aimmune Therapeutics Inc. is poised to bring to market the first broadly effective drug to help peanut allergy patients fend off ac.....»»
Peanut Allergy Almost Kills Woman Traveling for Life-Saving Treatment
The doctor who saved the allergic patient's life mid-flight happened to work at the clinic the woman was traveling to visit......»»
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatiti.....»»
Dua Lipa called out United Airlines because of a crew member’s alleged treatment of her sister’s severe peanut allergy
During her flight on Wednesday, singer Dua Lipa tweeted out against Unit.....»»
Glaxo, J&J"s Dual Drug HIV Regimen Succeeds in Phase III Study
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV. GlaxoSmithKline’s GSK HIV drug subsidiary-ViiV H.....»»
Stifel: DBV Tech Shares Attractive Ahead Of Potential 2019 Approval For Peanut Allergy Drug
Shares of DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT), a clinical-stage biotech developing treatment options for food allergies, present a favorable risk-reward profile over the next 12 months, according to Stifel. Latest Ratings for DBVT DateFirmAction.....»»